All Releases
 |
NeurogesX Reports First Quarter 2012 Results
May 3, 2012
|
21.0 KB |
|
| |
Q1 2012 and Recent Highlights:
Engaged JSB-Partners, a global life sciences advisor, to assist the Company in executing its business development objectives for NGX-1998 and Qutenza®
FDA accepted the Company's request for an End-of-Phase 2 meeting to discuss plans for Phase 3 development of the Company's next generation ...
|
|
NeurogesX to Hold Conference Call to Discuss First Quarter 2012 Results
Apr 27, 2012
|
10.2 KB |
|
| |
SAN MATEO, Calif., April 27, 2012 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain management therapies, today announced it will hold a conference call on Thursday, May 3, 2012, at 4:30 p.m. ET (1:30 p.m. PT) to report results for it...
|
|
NeurogesX Receives Determination Letter From NASDAQ
Apr 20, 2012
|
10.5 KB |
|
| |
SAN MATEO, Calif., April 20, 2012 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain management therapies, today announced that it received a determination letter from the Staff of The NASDAQ Stock Market LLC on April 17, 2012, indicat...
|
|
NeurogesX Engages JSB-Partners to Execute Business Development Strategy
Apr 17, 2012
|
12.9 KB |
|
| |
SAN MATEO, Calif., April 17, 2012 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain management therapies, today announced that it has engaged JSB-Partners, a global life sciences advisor, to assist the Company in executing its busines...
|
|
NeurogesX Provides Update on NGX-1998 Clinical Program
Apr 11, 2012
|
10.1 KB |
|
| |
SAN MATEO, Calif., April 11, 2012 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain management therapies, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's request for an End-of-Phase 2 meetin...
|
|
NeurogesX Reports Fourth Quarter and Year-End 2011 Results
Mar 8, 2012
|
26.4 KB |
|
| |
Q4 2011 and Recent Highlights:
Positive NGX-1998 Phase 2 clinical trial in postherpetic neuralgia (PHN) patients met all study objectives
Qutenza Q4 revenue totaled $3.0 million, including $0.8 million in product revenue
Sales to end user customers totaled $1.0 million
Ronald M...
|
|
NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Full Year 2011 Results
Feb 29, 2012
|
10.2 KB |
|
| |
SAN MATEO, Calif., Feb. 29, 2012 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain management therapies, today announced it will hold a conference call on Thursday, March 8, 2012 at 8:30 a.m. ET (5:30 a.m. PT) to report results for it...
|
|
NeurogesX Provides Update on Qutenza(R) (Capsaicin) 8% Patch for New Indication to Treat HIV-PN Following FDA Advisory Committee Review
Feb 9, 2012
|
14.5 KB |
|
| |
SAN MATEO, Calif., Feb. 9, 2012 (GLOBE NEWSWIRE) -- NeurogesX (Nasdaq:NGSX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain management therapies, today announced that the Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) to the U.S. Food and Drug Administration (FD...
|
|
NeurogesX' Stock Trading Halted Today
Feb 9, 2012
|
9.8 KB |
|
| |
SAN MATEO, Calif., Feb. 9, 2012 (GLOBE NEWSWIRE) -- NeurogesX Inc., a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain management, announced that NASDAQ has halted trading on the Company's common stock (Nasdaq:NGSX).
The Anesthetic and Analgesic Drug Products Advisory Committee...
|
|
NeurogesX Grants Equity Awards Under Its 2011 Inducement Stock Plan
Feb 3, 2012
|
10.3 KB |
|
| |
SAN MATEO, Calif., Feb. 3, 2012 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain management therapies, today announced that the Board of Directors granted equity awards under its 2011 Inducement Stock Plan (the "Plan") to its recentl...
|
|
NeurogesX, Inc. Announces $3.0 Million Private Placement
Feb 1, 2012
|
10.7 KB |
|
| |
SAN MATEO, Calif., Feb. 1, 2012 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced that on January 31, 2012 it entered into a securities purchase agreement in connection with a private placement to a group of institutional accredit...
|
|
NeurogesX Appoints Ronald Martell President and Chief Executive Officer
Jan 3, 2012
|
11.7 KB |
|
| |
SAN MATEO, Calif., Jan. 3, 2012 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced that the Board of Directors has appointed Ronald A. Martell as President and Chief Executive Officer, and a member of the board. Mr. Martell brings ...
|
|
NeurogesX Confirms FDA Advisory Committee to Review sNDA for Qutenza(R) (capsaicin) 8% Patch for HIV-Associated Peripheral Neuropathy (HIV-PN)
Dec 15, 2011
|
12.0 KB |
|
| |
SAN MATEO, Calif., Dec. 15, 2011 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today confirmed that the Division of Anesthesia, Analgesia and Addiction Products (DAAAP) of the U.S. Food and Drug Administration (FDA) has scheduled an Anestheti...
|
|
NeurogesX Receives FDA Acceptance for Review of sNDA for Qutenza(R) (capsaicin) 8% Patch for HIV-Associated Peripheral Neuropathy (HIV-PN)
Nov 14, 2011
|
13.0 KB |
|
| |
SAN MATEO, Calif., Nov. 14, 2011 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's supplemental new drug application (sNDA) for Qutenza® (...
|
|
NeurogesX to Present at Lazard Capital Markets 8th Annual Healthcare Conference
Nov 9, 2011
|
9.5 KB |
|
| |
SAN MATEO, Calif., Nov. 9, 2011 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that Anthony DiTonno, President and Chief Executive Officer, is scheduled to present at Lazard Capital Markets 8th Annual Healthcare Conference to b...
|
|
NeurogesX Reports Positive Phase 2 Results for NGX-1998 for Treatment of Postherpetic Neuralgia
Nov 8, 2011
|
15.3 KB |
|
| |
Study Results Support 5 Minute Application of Topical Liquid Capsaicin Formulation
Conference Call Today at 8:30am (ET)
SAN MATEO, Calif., Nov. 8, 2011 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today positive to...
|
|
NeurogesX Reports Third Quarter 2011 Results
Oct 31, 2011
|
26.3 KB |
|
| |
Recent Highlights:
Qutenza® (capsaicin) 8% patch U.S. launch progress includes:
Sales of Qutenza to end user customers reached $1.0 million in 3Q11, an increase of 22% over 2Q11
22% increase over 2Q11 in customers purchasing Qutenza
3Q11 revenue ...
|
|
NeurogesX Appoints Dr. Stephen J. Peroutka as Executive Vice President and Chief Medical Officer
Oct 31, 2011
|
12.3 KB |
|
| |
SAN MATEO, Calif., Oct. 31, 2011 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced the appointment of Stephen J. Peroutka, M.D., Ph.D., as Executive Vice President (EVP), and Chief Medical Officer (CMO). Dr. Peroutka will be respo...
|
|
NeurogesX to Hold Conference Call to Discuss Third Quarter 2011 Results
Oct 27, 2011
|
10.9 KB |
|
| |
SAN MATEO, Calif., Oct. 27, 2011 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced it will hold a conference call on Monday October 31, 2011 at 4:30 p.m. EDT (1:30 p.m. PDT) to report results for its third quarter ended September ...
|
|
NeurogesX Announces Resignation of EVP of Research and Development and Chief Medical Officer Jeffrey K Tobias, MD
Sep 27, 2011
|
10.6 KB |
|
| |
SAN MATEO, Calif., Sept. 27, 2011 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today the resignation of Jeffrey K Tobias MD, EVP, CMO effective October 16th, 2011. Dr. Tobias has agreed to serve as a consultant to the Company provi...
|
|
|
= add release to Briefcase